Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A01 and IC01 in advanced solid tumors
NCT03472352Phase 1Unknown
- Sponsor
- Hangzhou ConVerd Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of A01 and IC01 in solid tumor (advanced stage), sponsored by Hangzhou ConVerd Co., Ltd. Primary endpoint: Adverse events associated with infusion. Status: unknown.
02
Drugs
A01IC01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03472352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472352.